Safety and Efficacy BPC-157 has demonstrated a strong safety profile in various studies, with minimal side effects reported
Lancet 384 , 11961205 (2014)
Cagrilintide vs pramlintide (older amylin drug) Pramlintide (Symlin): FDA approved amylin analog for diabetes Short-acting (hours) Requires 2-3 daily injections Modest weight loss (2-4%) Inconvenient dosing Cagrilintide improvements: Long-acting (weekly) Much more convenient Higher weight loss (10-12%) Better pharmacokinetics Longer duration of action Why cagrilintide is better: Weekly dosing = better adherence Stable drug levels More consistent appetite suppression Greater cumulative effect Modern drug design See our peptides for weight loss , best peptides for weight loss , and best peptide stack for weight loss at SeekPeptides
Mitchel, KG, Feldman, HA, Milton, D, Antonoff, MB , Hofstetter, WL, Rice, DC, Vaporciyan, AA, Lin, R, Thall, PF, Rajaram, R
Seventy percent